Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer could reveal hidden cancer clues without a biopsy

NCT ID NCT07459192

Diagnosis Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new radioactive tracer called 68Ga-DOTA-BLP for PET scans to see PD-L1 levels in tumors. PD-L1 helps cancer hide from the immune system, and knowing its levels can guide immunotherapy. The study will include 50 adults with confirmed cancer and suspicious spots on scans. The goal is to see if this imaging method is accurate and safe.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
68Ga-DOTA-BLP (a radioactive tracer for PET scans)
What this could lead to
If successful, this could lead to a more accurate, non-invasive way to see PD-L1 levels in tumors, helping doctors choose the right immunotherapy for each patient.
What could go wrong
This is a small, early-stage study (50 people) that hasn't started yet. The new imaging method may not be more accurate than existing tests, and results may not apply to all cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with malignant tumors confirmed by biopsy or surgical pathology.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age over 18 years, gender not restricted; * patients with malignant tumors confirmed by biopsy or surgical pathology; * Imaging findings of suspicious lymph nodes or distant metastases; * informed consent signed in writing by the subject or his/her legal guardian. Exclusion Criteria: * patients who have received antitumor therapy prior to PET/CT or PET/MR scanning; * Patients with severe medical conditions who cannot tolerate PET/CT or PET/MR scans; * The alternative subjects have contraindications to PET/CT or PET/MR scans; * exposure to radiation of more than 50 mSv in the past year; * The alternative subjects underwent major surgery within the past 3 months; received experimental drug or device therapy (with unclear efficacy or safety) within the past 1 month; * The alternative subjects had any clinical conditions that the principal investigator of this study considered to be potentially harmful or associated with the formulation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANSER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANSER

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Daping Hospital, Army Medical University

    Chongqing, Chognqing, 400010, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.